Recent trends in epidemiology of brain metastases: An overview

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4655-4662

  Tabouret, Emeline ^a,c   Chinot, Olivier ^a,c   Metellus, Philippe ^a,c   Tallet, Agnès ^b   Viens, Patrice ^b,c   Gonçalves, Anthony ^b,c  

^a TIMONE HOSPITAL   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Brain metastases; Breast cancer; Epidemiology; Lung cancer; Review

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB;

AGE DISTRIBUTION; BRAIN METASTASIS; BRAIN SURGERY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; ECONOMIC ASPECT; HUMAN; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; SURVIVAL TIME;

BRAIN NEOPLASMS; HUMANS; INCIDENCE; PREVALENCE;

EID: 84872656616     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Counsell CE, Collie DA and Grant R: Incidence of intracranial tumours in the Lothian region of Scotland, 1989-90. J Neurol Neurosurg Psychiatry 61: 143-150, 1996.
2. Walker AE, Robins M and Weinfeld FD: Epidemiology of brain tumors: The National Survey of intracranial neoplasms. Neurology 35: 219-226, 1985.
3. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37: 745-751, 1997.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
7. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA and Edwards BK: Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103: 714-736, 2011.
8. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236, 2011.
9. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben HM, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L and Mueller RP: Adjuvant whole-brain radiotherapy versusobservation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29: 134-141, 2011.
10. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS and Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494-500, 1990.
11. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F and Winer EP: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26: 1993-1999, 2008.
12. Langer CJ and Mehta MP: Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207-6219, 2005.
13. Schouten LJ, Rutten J, Huveneers HA and Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94: 2698-2705, 2002.
14. Smedby KE, Brandt L, Backlund ML and Blomqvist P: Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 101: 1919-1924, 2009.
15. Nieder C, Spanne O, Mehta MP, Grosu AL and Geinitz H: Presentation, patterns of care, and survival in patients with brain metastases: What has changed in the last 20 years? Cancer 2010.
16. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, and Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872, 2004.
17. Gril B, Evans L, Palmieri D and Steeg PS: Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer 46: 1204-1210, 2010.
18. Lin NU and Winer EP: Brain metastases: The HER2 paradigm. Clin Cancer Res 13: 1648-1655, 2007.
19. Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, Michiara M, Silini EM and Ardizzoni A: Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 117(9): 1837-1846, 2010.
20. Nathoo N, Toms SA and Barnett GH: Metastases to the brain: Current management perspectives. Expert Rev Neurother 4: 633-640, 2004.
21. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS and Goldhirsch A: Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17: 935-944, 2006.
22. Frisk G, Svensson T, Backlund LM, Lidbrink E, Blomqvist P and Smedby KE: Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer 106: 1850-1853, 2012.
23. Pelletier EM, Shim B, Goodman S and Amonkar MM: Epidemiology and economic burden of brain metastases among patients with primary breast cancer: Results from a US claims data analysis. Breast Cancer Res Treat 108: 297-305, 2008.
24. Nieder C, Pawinski A and Balteskard L: Colorectal cancer metastatic to the brain: Time trends in presentation and outcome. Oncology 76: 369-374, 2009.
25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
26. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR: K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versusinterferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
28. Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB and Gore ME: Epithelial ovarian cancer metastasizing to the brain: A late manifestation of the disease with an increasing incidence. J Clin Oncol 20: 982-986, 2002.
29. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
30. Pickren JW, Lopez G, Tsukada Y and Lane WW: Brain metastases: An autopsy study. Cancer Treat Symp 2: 295-313, 1983.
31. Posner JB and Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol 19: 579-592, 1978.
32. Percy AK: Neoplasms of the central nervous system: Epidemiologic considerations. Neurology 20: 398-399, 1970.
33. Tsukada Y, Fouad A, Pickren JW and Lane WW: Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52: 2349-2354, 1983.
34. Fox BD, Cheung VJ, Patel AJ, Suki D and Rao G: Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 22: 1-6, v, 2011.
35. Gavrilovic IT and Posner JB: Brain metastases: Epidemiology and pathophysiology. J Neurooncol 75: 5-14, 2005.
36. Nieder C, Marienhagen K, Geinitz H and Molls M: Validation of the graded prognostic assessment index for patients with brain metastases. Acta Oncol 48: 457-459, 2009.
37. Sperduto PW, Berkey B, Gaspar LE, Mehta M and Curran W: A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70: 510-514, 2008.
38. Villa S, Weber DC, Moretones C, Manes A, Combescure C, Jove J, Puyalto P, Cuadras P, Bruna J, Verger E, Balana C and Graus F: Validation of the new Graded Prognostic Assessment scale for brain metastases: A multicenter prospective study. Radiat Oncol 6: 23-31, 2011.
39. Schootman M, Jeffe DB, Gillanders WE and Aft R: Racial disparities in the development of breast cancer metastases among older women: A multilevel study. Cancer 115: 731-740, 2009.
40. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, and Henson JW: Survival in patients with brain metastases from breast cancer: The importance of HER-2 status. Cancer 112: 2359-2367, 2008.
41. Lin NU, Bellon JR, and Winer EP: CNS metastases in breast cancer. J Clin Oncol 22: 3608-3617, 2004.
42. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM and Carey LA: The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117(8): 1602-1611, 2010.
43. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A and du BA: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792-2798, 2009.
44. Yawn BP, Wollan PC, Schroeder C, Gazzuola L and Mehta M: Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med 86: 32-37, 2003.
45. Bajard A, Westeel V, Dubiez A, Jacoulet P, Pernet D, Dalphin JC and Depierre A: Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer 45: 317-323, 2004.
46. Delattre JY, Krol G, Thaler HT and Posner JB: Distribution of brain metastases. Arch Neurol 45: 741-744, 1988.
47. Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, Moscetti L, Russillo M, Lanzetta G, Mansueto G, Pace A, Maschio M, Vidiri A, Sperduti I, Cognetti F and Carapella CM: Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res 30: 10-17, 2011.
48. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM and Johnson BE: Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16: 5873-5882, 2010.
49. Ogawa S, Horio Y, Yatabe Y, Fukui T, Ito S, Hasegawa Y, Mitsudomi T and Hida T: Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer. Int J Clin Oncol 17: 218-224, 2011.
50. Vuong DA, Rades D, Vo SQ and Busse R: Extracranial metastatic patterns on occurrence of brain metastases. J Neurooncol 105: 83-90, 2011.
51. Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB and Aquino SL: Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol 1: 205-210, 2006.
52. Sheehan J, Kondziolka D, Flickinger J and Lunsford LD: Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: Outcomes and prognostic factors. J Neurosurg 102(Suppl): 247-254, 2005.
53. Sheehan JP, Sun MH, Kondziolka D, Flickinger J and Lunsford LD: Radiosurgery for non-small cell lung carcinoma metastatic to the brain: Long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 97: 1276-1281, 2002.
54. Le SR, Massard C, Mouret-Fourme E, Guinebretierre JM, Cohen-Solal C, De LB, Moisson P, Breton-Callu C, Gardner M, Goupil A, Renody N, Floiras JL and Labib A: Brain metastases from breast carcinoma: Validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys 69: 839-845, 2007.
55. Niwinska A, Murawska M and Pogoda K: Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 116:4238-4247, 2010.
56. Niwinska A, Murawska M and Pogoda K: Breast cancer brain metastases: Differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21: 942-948, 2010.
57. Andrews DW: Should surgery followed by whole-brain radiation therapy be the standard treatment for single brain metastasis? Nat Clin Pract Oncol 5: 572-573, 2008.
58. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC and Linskey ME: The role of surgical resection in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 33-43, 2010.
59. Paek SH, Audu PB, Sperling MR, Cho J and Andrews DW: Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 56: 1021-1034, 2005.
60. Barker FG: Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: Decreasing mortality and the effect of provider caseload. Cancer 100: 999-1007, 2004.
61. Patchell RA, Regine WF, Loeffler JS, Sawaya R, Andrews DW and Chin LS: Radiosurgery plus whole-brain radiation therapy for brain metastases. JAMA 296: 2089-2090, 2006.
62. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP and Curran WJ Jr.: Whole-brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363: 1665-1672, 2004.
63. Davey P, Hoegler D, Ennis M and Smith J: A phase III study of accelerated versus conventional hypofractionated whole-brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol 88:173-176, 2008.
64. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC and Kalkanis SN: The role of whole-brain radiation therapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 17-32, 2010.
65. Patel RR and Mehta MP: Targeted therapy for brain metastases: Improving the therapeutic ratio. Clin Cancer Res 13: 1675-1683, 2007.
66. Andrews DW: Current neurosurgical management of brain metastases. Semin Oncol 35: 100-107, 2008.
67. Andrews RJ, Gluck DS and Konchingeri RH: Surgical resection of brain metastases from lung cancer. Acta Neurochir (Wien) 138: 382-389, 1996.
68. Frazier JL, Batra S, Kapor S, Vellimana A, Gandhi R, Carson KA, Shokek O, Lim M, Kleinberg L and Rigamonti D: Stereotactic radiosurgery in the management of brain metastases: An institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys 76: 1486-1492, 2010.
69. Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL and Sneed PK: Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg 109(Suppl): 77-86, 2008.
70. Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, Olson C, Whitton A, Movsas B and Curran W: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39: 571-574, 1997.
71. Guerrieri M, Wong K, Ryan G, Millward M, Quong G and Ball DL: A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46: 107-111, 2004.
72. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Olson JJ, Patchell RA, Ryken TC and Kalkanis SN: The role of chemotherapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 71-83, 2010.
73. Melisko ME, Moore DH, Sneed PK, De FJ and Rugo HS: Brain metastases in breast cancer: Clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 88: 359-365, 2008.
74. Pesce GA, Klingbiel D, Ribi K, Zouhair A, von MR, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M and Stupp R: Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole-brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 48: 377-384, 2011.
75. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N and Mehta M: Summary report on the Graded Prognostic Assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30: 419-425, 2012.
76. Kruser TJ, Chao ST, Elson P, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Pelley R and Suh JH: Multidisciplinary management of colorectal brain metastases: A retrospective study. Cancer 113: 158-165, 2008.
77. Devito N, Yu M, Chen R and Pan E: Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. Anticancer Res 31: 4537-4543, 2011.
78. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN and Gonzalez-Angulo AM: Survival among women with triple receptornegative breast cancer and brain metastases. Ann Oncol 20: 621-627, 2009.
79. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A and Winer EP: Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 113: 2638-2645, 2008.
80. Church DN, Modgil R, Guglani S, Bahl A, Hopkins K, Braybrooke JP, Blair P and Price CG: Extended survival in women with brain metastases from HER2-overexpressing breast cancer. Am J Clin Oncol 31: 250-254, 2008.
81. Heitz F, Rochon J, Harter P, Lueck HJ, Fisseler-Eckhoff A, Barinoff J, Traut A, Lorenz-Salehi F and du BA: Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Ann Oncol 22: 1571-1581, 2011.
82. Lai R, Dang CT, Malkin MG and Abrey LE: The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101: 810-816, 2004.
83. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J and Sledge GW Jr.: Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14: 1072-1077, 2003.